INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 180 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 1.51 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $651 | -58.3% | 35,087 | -75.2% | 0.01% | -53.8% |
| Q2 2023 | $1,562 | +49.9% | 141,219 | +82.1% | 0.01% | +44.4% |
| Q1 2023 | $1,042 | -84.1% | 77,558 | -85.4% | 0.01% | -90.5% |
| Q4 2022 | $6,563 | -99.4% | 530,567 | +532.1% | 0.10% | +533.3% |
| Q3 2022 | $1,171,000 | +107.3% | 83,939 | +141.6% | 0.02% | +114.3% |
| Q1 2022 | $565,000 | -78.0% | 34,745 | -78.0% | 0.01% | -74.1% |
| Q4 2021 | $2,568,000 | +504.2% | 157,663 | +450.6% | 0.03% | +350.0% |
| Q3 2021 | $425,000 | +100.5% | 28,633 | +169.2% | 0.01% | +200.0% |
| Q2 2021 | $212,000 | -49.2% | 10,635 | -41.1% | 0.00% | -66.7% |
| Q1 2021 | $417,000 | -10.9% | 18,055 | -4.6% | 0.01% | +20.0% |
| Q4 2020 | $468,000 | -76.1% | 18,929 | -53.8% | 0.01% | -90.2% |
| Q2 2020 | $1,961,000 | +623.6% | 40,941 | +1104.1% | 0.05% | +363.6% |
| Q2 2019 | $271,000 | +34.8% | 3,400 | +89.3% | 0.01% | -26.7% |
| Q1 2019 | $201,000 | – | 1,796 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |